ArticleFrontiers in pharmacology2021
Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Pooled it
- Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review.Frontiers in public health · 2024Pooled it
- Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- Application of Actor Network Theory to Evaluate Supply and Demand Strategies Used to Encourage International Biosimilar Uptake.Pharmaceutical medicine · 2026Review
- Biological Medicines, Biosimilars and Their Automatic Substitution: Concerns, Knowledge and Information Needs of People with Diabetes.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Article
- Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades.Journal of pharmaceutical policy and practice · 2026Review
- Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Article
- Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan.Journal of pharmaceutical policy and practice · 2026Article
- Barriers to adoption of biosimilar insulins in Europe: A mixed-methods study.Diabetes, obesity & metabolism · 2025Article
- Patient knowledge and acceptance of the upcoming automatic substitution of biological medicines in community pharmacies: survey of Finnish patients with inflammatory bowel disease and psoriasis.BMC health services research · 2025Article
- Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024.Pharmacy (Basel, Switzerland) · 2025Article
- Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries.BMJ open · 2025Article
- A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability.Frontiers in pharmacology · 2025Article
- The need to update Ethiopia's national health and medicine policies: essential tools for informed decision-making in healthcare and the pharmaceutical sectors.Frontiers in public health · 2025Article
- Improving antibiotic prescribing - Recommendations for funding and pricing policies to enhance use of point-of-care tests.Health policy OPEN · 2024Article
- Biosimilars in the Era of Artificial Intelligence-International Regulations and the Use in Oncological Treatments.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.